

【Therapeutic category】 Agents affecting metabolism, n.e.c. (not elsewhere classified)
【Non-proprietary name】 Azathioprine
【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current	Revision
11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions N/A	11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Posterior reversible encephalopathy syndrome</u> <u>If symptoms such as headache, disturbed consciousness, seizures, hypertension, visual disturbances etc. are observed, diagnostic imaging through MRI should be performed, administration should be discontinued, and appropriate measures, including blood pressure control and administration of anticonvulsants, should be taken.</u> <u>Sinusoidal obstruction syndrome (SOS) /Veno-occlusive disease (VOD)</u> <u>SOS/VOD, including non-cirrhotic portal hypertension, may occur. If symptoms such as increased levels of bilirubin, ascites, rapid weight gain, and hepatomegaly are observed, administration should be discontinued, and appropriate measures should be taken.</u>

N/A: Not Applicable. No corresponding description is included in the current PRECAUTIONS.